THE EFFECT OF GLUCOVANCE THERAPY ON BIOMECHANICAL DETERIORATION OF BONE IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

Area of Science:

• Biomedical Science
• Endocrinology
• Orthopedics

Background:

• Diabetes mellitus (DM) is associated with significant bone health complications.
• Streptozotocin (STZ)-induced diabetes in rats is a common model to study these effects.
• Understanding the impact of DM on bone biomechanics is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the effects of Glucovance therapy on the biomechanical properties of bone in a rat model of STZ-induced diabetes.
• To assess whether Glucovance can mitigate bone deterioration caused by diabetes.

Main Methods:

• Twenty-eight male Wistar-Albino rats were divided into four groups: control, sham, diabetes (DM), and diabetes with Glucovance treatment (DM+G).
• Diabetes was induced using a single intraperitoneal injection of streptozotocin (45 mg/kg).
• The DM+G group received Glucovance (500/5 mg/kg/day) for 8 weeks. Body weight, blood glucose levels, bone mineral density, and bone biomechanical properties were evaluated.

Main Results:

• Diabetic rats exhibited significantly increased blood glucose levels and decreased body weights compared to non-diabetic rats.
• In diabetic rats, bone stiffness increased, while maximum load, energy absorption, ultimate stress, ultimate strain, and toughness decreased.
• Glucovance treatment in diabetic rats (DM+G) significantly increased ultimate stress and maximum load compared to the untreated diabetic group (DM).

Conclusions:

• Glucovance therapy demonstrates efficacy in restoring biomechanical deterioration of bone in STZ-induced diabetes mellitus.
• These findings suggest Glucovance may be a beneficial therapeutic option for managing bone complications associated with diabetes.